Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial" is generating significant coverage in the Business category, with 6 articles from 6 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Yahoo Finance, Kalkine Media, CancerNetwork and BioPharma Dive. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 143d ago.
Quick answers
Why is "Pfizer’s first new ADC from Seagen acquisition fails phase 3 NSCLC trial" trending?
Because 6 independent news sources published 6 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (6)
- Pfizer's Mixed Phase III Data for Sigvotatug Vedotin in NSCLC Yahoo Finance · 146d ago
- Can Pfizer (NYSE:PFE) Clear Its Latest Oncology Hurdle? Kalkine Media · 146d ago
- Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial CancerNetwork · 146d ago
- Pfizer drug acquired in Seagen deal disappoints in lung cancer study BioPharma Dive · 146d ago
- Sigvotatug Vedotin Fails to Improve OS in Advanced, Pretreated Nonsquamous NSCLC OncLive · 146d ago
- Pfizer's $43B Seagen bet sours further as ADC fails in late-stage lung cancer trial Endpoints News · 146d ago
Topics
Related trends
Pfizer hikes full-year outlook as newer products grow, taps company veteran as new CFO
Pfizer has increased its 2026 full-year guidance following strong third-quarter results driven by growth in cancer and migraine medications.
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
Genmab releases new phase 2 data for its antibody-drug conjugate, prompting claims of superiority over rival treatments.
Vaxcyte’s stock jumps as pneumococcal vaccine holds its own against Pfizer's, Merck’s shots
Vaxcyte stock surges following phase 3 trial results for its pneumococcal vaccine candidate in a lucrative market.
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
What you need to know about this year’s fall vaccines
Health authorities and medical groups are updating guidance for the 2026 fall respiratory vaccine season, including new cost structures in Australia.
Pfizer Covid Pill Revenue Plunges 95%. Why Earnings Are Lifting the Stock Anyway.
Pfizer's stock is rising after beating earnings estimates, despite a 95% plunge in revenue from its Covid pill.